InspireMD (NYSE:NSPR) Research Coverage Started at assumed coverage on shares of InspireMD (NYSE:NSPRGet Rating) in a research note issued on Wednesday. The brokerage set a “sell” rating on the stock.

Shares of NSPR opened at $1.93 on Wednesday. The stock’s 50-day moving average is $2.30. The firm has a market capitalization of $16.06 million, a PE ratio of -0.92 and a beta of 1.39. InspireMD has a 12 month low of $1.80 and a 12 month high of $6.82.

About InspireMD (Get Rating)

InspireMD, Inc, a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions, as well as bypass surgery.

See Also

Want More Great Investing Ideas?

Receive News & Ratings for InspireMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InspireMD and related companies with's FREE daily email newsletter.